Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis (UC)

28. April 2020 aktualisiert von: Amgen

A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in participants with active Ulcerative Colitis (UC).

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Approximately 165 participants (55 subjects per arm) will be randomized in a 1:1:1 ratio to receive oral apremilast (30 mg BID or 40 mg BID), or identically appearing placebo BID for up to 12 weeks, followed by 40 weeks of blinded treatment with apremilast (30 mg BID or 40 mg BID).

At the end of the Blinded Active-treatment Phase (Week 52), participants who have a Mayo endoscopy score ≤ 1 will have the opportunity to participate in the Extension Phase. Participants enrolled in the Extension Phase will receive apremilast for an additional 52 weeks (Weeks 52 to 104). With the implementation of Amendment 4, participants entering the Extension Phase will receive apremilast 30 mg BID. Subjects currently in the Extension Phase who are receiving apremilast 40 mg BID will be switched to 30 mg BID at the next scheduled visit.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

170

Phase

  • Phase 2

Erweiterter Zugriff

Nicht länger verfügbar außerhalb der klinischen Studie. Siehe erweiterter Zugriffsdatensatz.

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Australien
    • New South Wales
      • Concord, New South Wales, Australien, 2139
        • Concord Repatriation General Hospital
      • Liverpool, New South Wales, Australien, 2170
        • Liverpool Hospital
    • Queensland
      • South Brisbane, Queensland, Australien, 4101
        • Mater Adult Hospital
    • Victoria
      • Footscray, Victoria, Australien, 3011
        • Footscray Hospital
      • Parkville, Victoria, Australien, 3050
        • Royal Melbourne Hospital
  • Bulgarien
      • Plovdiv, Bulgarien, 4002
        • Multiprofile Hospital for Active Treatment Kaspela
      • Sofia, Bulgarien, 1303
        • Medical Center Asklepion - Humane Medicine Research EOOD
      • Sofia, Bulgarien, 1431
        • University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD
      • Sofia, Bulgarien, 1407
        • University Multiprofile Hospital for Active Treatment ACIBADEM City Clinic Sofia
      • Sofia, Bulgarien, 1527
        • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD
      • Sofia, Bulgarien, 1784
        • Clinic of Gastroenterology
      • Varna, Bulgarien, 9010
        • Multiprofile Hospital for Active Treatment Sveta Marina EAD
  • Deutschland
      • Berlin, Deutschland, 14050
        • DRK Kliniken Berlin Westend
      • Frankfurt, Deutschland, 60594
        • Crohn-Colitis-Centre Rhein-Main
      • Keil, Deutschland, 24105
        • Universitätsklinikum Schleswig-Holstein
      • Minden, Deutschland, 32423
        • Gastroenterologische Praxis Minden
  • Frankreich
      • Amiens, Frankreich, 80054
        • Amiens University Hospital
      • Clichy, Frankreich, 92110
        • Hopital Beaujon
      • Nantes, Frankreich, 602 00
        • CHRU Nantes
      • Nice, Frankreich, 06202
        • CHU de Nice Archet I
      • Pierre Bénite, Frankreich, 69495
        • Centre Hospitalier Lyon Sud
      • Saint Priest en Jarez, Frankreich, 42055
        • Centre Hospitalier Universitaire de Saint Etienne
      • Vandoeuvre les Nancy, Frankreich, 54511
        • Chru Nancy
  • Italien
      • Bologna, Italien, 40138
        • Azienda Ospedaliero Universitaria Di Bologna Policlinico Sorsola Malpighi
      • Milan, Italien, 20089
        • IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center
      • Palermo, Italien, 90146
        • Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello
      • Roma, Italien, 00168
        • Complesso Integrato Columbus
      • Roma, Italien, 00133
        • Fondazione PTV Policlinico Tor Vergata
  • Kanada
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3A 1R9
        • Winnipeg Regional Health Authority - Health Sciences Centre
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • Hamilton Health Sciences Corporation, McMaster University Medical Centre
  • Neuseeland
      • Auckland, Neuseeland, 1023
        • Auckland City Hospital
      • Christchurch, Neuseeland, 8011
        • Christchurch Hospital
      • Dunedin, Neuseeland, 9016
        • Dunedin Hospital
      • Hamilton, Neuseeland, 3204
        • Waikato Hospital
  • Niederlande
      • Groningen, Niederlande, 9713 GZ
        • Universitair Medisch Centrum Groningen
      • Rotterdam, Niederlande, 3083 AN
        • Ikazia Ziekenhuis
  • Polen
      • Bialystok, Polen, 15-276
        • Uniwersytecki Szpital Kliniczny w Bialymstoku
      • Bydgoszcz, Polen, 85-794
        • Osrodek Badan Klinicznych CLINSANTE S.C.
      • Czestochowa, Polen, 42 202
        • Centrum Medyczne Sw. Lukasza
      • Katowice, Polen, 40 659
        • Economicus - NZOZ ALL-MEDICUS
      • Sopot, Polen, 81-756
        • Endoskopia Sp. z o.o.
      • Szczecin, Polen, 71-685
        • Sonomed Sp. z o.o.
      • Torun, Polen, 40 659
        • Gastromed Kopon Zmudzinski i Wspolnicy Sp. j. Specjalistyczne Centrum Gastrologii i Endoskopii Spec. Gabinety Lekarskie
      • Warsaw, Polen, 00-632
        • Centrum Zdrowia Matki, Dziecka i Mlodziezy
      • Warszawa, Polen, 03-563
        • Niepubliczny Zaklad Opieki Zdrowotnej VIVAMED
      • Wroclaw, Polen, 03-580
        • Lexmedica Drubajlo Hanna
      • Wroclaw, Polen, 53-333
        • ARS Médica
  • Russische Föderation
      • Kazan, Russische Föderation, 420064
        • Republican Clinical Hospital
      • Moscow, Russische Föderation, 115088
        • Stolitsa-Medikl, LLC
      • Rostov on Don, Russische Föderation, 344022
        • SEIHPE Rostov State Medical University of MoH of RF
      • Saratov, Russische Föderation, 410053
        • Regional Clinical Hospital
      • St Petersburg, Russische Föderation, 129329
        • Russian Medical Military Academy na SMKirov
  • Tschechien
      • Brno, Tschechien, 656 91
        • Fakultni nemocnice u sv Anny v Brne
      • Hradec Kralove, Tschechien, 500 05
        • Fakultni nemocnice Hradec Kralove
      • Hradec Králové, Tschechien, 500 12
        • Hepato-Gastroenterologie HK, s. r. o.
      • Slany, Tschechien, 274 01
        • Nemocnice Slany
  • Ukraine
      • Ivano-Frankivsk, Ukraine, 76018
        • Ivano-Frankivsk Central City Clinical Hospital
      • Ivano-Frankivsk, Ukraine, 58001
        • Regional Clinical Hospital, Gastroenterology department, State Higher Education Institute Ivano-Frankivsk National Medical University
      • Ivano-Frankivsk, Ukraine, 76008
        • Ivano-Frankivsk Regional Clinical Hospital
      • Kharkiv, Ukraine, 61037
        • Kharkiv City Clinical Hospital 2
      • Kirovograd, Ukraine, 25006
        • Private Enterprise Private Manufacture Company Acinus
      • Kremenchuk, Ukraine, 39617
        • Kremenchuk City Hospital # 1 n.a O.T.Bohaievskyi
      • Lviv, Ukraine, 79059
        • Lviv Emergency Clinical Hospital, Therapeutics Department No. 1
      • Odesa, Ukraine, 65025
        • Municipal Institution Odesa Regional Clinical Hospital
      • Uzhgorod, Ukraine, 88000
        • Central City Clinical Hospital
      • Vinnytsia, Ukraine, 21018
        • Vinnytsia Regional Clinical Hospital n a M I Pyrohov
      • Zaporizhzhia, Ukraine, 69600
        • Municipal Institution Zaporizhzhia
  • Ungarn
      • Budapest, Ungarn, 1139
        • Endomedix Kft.
      • Budapest, Ungarn, 1136
        • Pannonia Maganorvosi Centrum Kft.
      • Debrecen, Ungarn, 4025
        • Vasútegészségügyi Nonprofit Kiemelten Közhasznú Kft. Debreceni Egészségügyi Központja
      • Mosonmagyaróvár, Ungarn, 9200
        • Karolina Korhaz Rendelointezet
      • Szeged, Ungarn, 6720
        • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
      • Szekszárd, Ungarn, 7100
        • Tolna Megyei Balassa Janos Korhaz
      • Vác, Ungarn, 2600
        • Javorszky Odon Korhaz
  • Vereinigte Staaten
    • Alabama
      • Dothan, Alabama, Vereinigte Staaten, 36305
        • Digestive Health Specialists of the Southeast
    • California
      • Los Angeles, California, Vereinigte Staaten, 90045
        • Southern California Research Institute Medical Group, Inc.
    • Connecticut
      • Bristol, Connecticut, Vereinigte Staaten, 06010
        • Connecticut Clinical Research Foundation
    • Florida
      • Boynton Beach, Florida, Vereinigte Staaten, 33426
        • Consultants for Clinical Research of South Florida
      • DeLand, Florida, Vereinigte Staaten, 32720
        • Avail Clinical Research, LLC
      • Lauderdale Lakes, Florida, Vereinigte Staaten, 33319
        • Precision Clinical Research, LLC
      • Miami, Florida, Vereinigte Staaten, 33126
        • Pharmax Research Clinic, Inc.
      • Naples, Florida, Vereinigte Staaten, 34102
        • Gastroenterology Group Of Naples
      • Port Orange, Florida, Vereinigte Staaten, 32127
        • Advanced Medical Research Center
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60637
        • University of Chicago Medical Center
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa Hospitals and Clinics
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40202
        • University of Louisville
    • Massachusetts
      • Worcester, Massachusetts, Vereinigte Staaten, 01655
        • UMASS Medical Center
    • Michigan
      • Chesterfield, Michigan, Vereinigte Staaten, 48047
        • Clinical Research Institute of Michigan, LLC
      • Troy, Michigan, Vereinigte Staaten, 48098
        • Center for Digestive Health Research
    • Mississippi
      • Flowood, Mississippi, Vereinigte Staaten, 39232
        • Gastrointestinal Associates PA
    • New York
      • Great Neck, New York, Vereinigte Staaten, 11021
        • NYU Langone Long Island Clinical Research Associates
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • Consultants for Clinical Research
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37211
        • Quality Medical Research
    • Texas
      • Live Oak, Texas, Vereinigte Staaten, 78233
        • Digestive Research Center/ Gastroenterology Consultants of San Antonio
      • Pasadena, Texas, Vereinigte Staaten, 77505
        • Digestive Health Specialist of Tyler
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • San Antonio Gastroenterology
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84132
        • University of Utah
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98195
        • University of Washington Medical Center
      • Seattle, Washington, Vereinigte Staaten, 98104
        • Harborview Medical Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

  • Male or female aged 18 and over at the time of signing the informed consent.
  • Must understand and voluntarily sign an informed consent form prior to any study related assessments/procedures being conducted.
  • Diagnosis of ulcerative colitis (UC) with a duration of at least 3 months prior to the Screening Visit..
  • Total Mayo Score (TMS) ≥ 6 to ≤ 11 (range: 0-12) at baseline, prior to randomization in the study.
  • Endoscopic subscore ≥ 2 (range: 0-3) on the Mayo score prior to randomization in the study.
  • Subjects must have had a therapeutic failure, been intolerant to, or have a contraindication to, at least one of the following: oral aminosalicylates (ie, 5-aminosalicylic acid [5-ASA] compounds or sulfasalazine [SSZ]), budesonide, systemic corticosteroids, or immunosuppressants (eg, 6-mercaptopurine [6-MP], azathioprine [AZA], or methotrexate [MTX]).

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  • Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.
  • Ulcerative colitis restricted to the distal 15 cm or less (eg, ulcerative proctitis).
  • Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study.
  • Clinical signs suggestive of fulminant colitis or toxic megacolon.
  • Prior use of any tumor necrosing factor (TNF) inhibitor (or any biologic agent).
  • Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine or thalidomide.
  • Use of intravenous (IV) corticosteroids within 2 weeks of the Screening Visit.
  • Use of immunosuppressants (AZA, 6-MP or MTX) within 8 weeks of the Screening Visit.
  • Use of topical treatment with 5-ASA or corticosteroid enemas or suppositories within 2 weeks of the Screening Visit.
  • History of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would preclude participation in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Apremilast 30 mg PO BID

Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks

After 12 weeks:

  • Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)
  • Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)

After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Arzneimittel: Apremilast
Andere Namen:
  • CC-10004; Ötezla
Experimental: Apremilast 40 mg PO BID

Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks

After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)

After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)
Arzneimittel: Apremilast
Andere Namen:
  • CC-10004; Ötezla
Placebo-Komparator: Placebo BID

Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)

After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)
Arzneimittel: Placebo
Arzneimittel: Apremilast
Andere Namen:
  • CC-10004; Ötezla

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Who Achieved a Clinical Remission by Total Mayo Score (TMS) at Week 12
Zeitfenster: Week 12

Clinical remission was defined as a total Mayo score ≤ 2 points, with no individual subscore exceeding 1 point. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

  • Stool Frequency Subscore (SFS)
  • Rectal Bleeding Subscore (RBS)
  • Endoscopy Subscore
  • Physician's Global Assessment (PGA). Two-sided 95% confidence intervals (CI) for the within-group percentages are based on the Wilson score method.
Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score and the Reduction in the Rectal Bleeding Subscore at Week 12
Zeitfenster: Week 12

Clinical response was defined as a decrease from baseline in the TMS of at least 3 points and at least 30%, along with a reduction in the rectal bleeding subscore (RBS) of at least 1 point or an absolute RBS of ≤ 1. The TMS is an instrument designed to measure disease activity of UC. The Mayo score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

  • Stool Frequency Subscore (SFS)
  • Rectal Bleeding Subscore
  • Endoscopy Subscore
  • Physician's Global Assessment (PGA)

Rectal bleeding (subscore 0-3) was defined as:

0 = No blood seen

  1. = Streaks of blood with stool less than half the time
  2. = Obvious blood with stool
  3. = Blood alone passes Two-sided 95% CI for the within-group percentages are based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved an Endoscopic Remission at Week 12
Zeitfenster: Week 12

An endoscopic remission was defined as a Mayo endoscopic subscore (MES) of 0 at Week 12.

The MES subscore findings were defined as:

0 = Normal or inactive disease

  1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
  2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
  3. = Severe Disease (spontaneous bleeding, ulceration)

The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved an Endoscopic Response at Week 12
Zeitfenster: Week 12

An endoscopic response is defined as a decrease from baseline of at least 1 point in the MES at Week 12. The Mayo endoscopy subscore findings were defined as:

0 = Normal or inactive disease

  1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
  2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3 = Severe Disease (spontaneous bleeding, ulceration).

The endoscopy subscores consisted of findings that were centrally read through proctosigmoidoscopy, graded from 0 to 3 with higher scores indicating more severe disease. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved a Rectal Bleeding Subscore (RBS) of ≤ 1 at Week 12
Zeitfenster: Week 12

The RBS was measured as:

0 = No blood seen

  1. = Streaks of blood with stool less than half the time
  2. = Obvious blood with stool most of the time
  3. = Blood alone passes

The daily bleeding score represents the most severe bleeding of the day. Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Subscore (MMS) at Week 12
Zeitfenster: Week 12
Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore > 1, at Week 12. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved Clinical Response in the Modified Mayo Subscore (MMS) at Week 12
Zeitfenster: Week 12

Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity.

The RBS was measured as:

0 = No blood seen

  1. = Streaks of blood with stool less than half the time
  2. = Obvious blood with stool most of the time
  3. = Blood alone passes

The daily bleeding score represents the most severe bleeding of the day. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.
Week 12
Percentage of Participants Who Achieved Clinical Remission in the Partial Mayo Subscore (PMS) With no Individual Subscore >1 at Week 8
Zeitfenster: Week 8

Clinical remission in the partial Mayo subscore was defined as a PMS of 2 points or lower, with no individual subscore >1. The PMS is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:

Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Week 8
Percentage of Participants Who Achieved Clinical Response in the Partial Mayo Subscore at Week 8
Zeitfenster: Week 8

Clinical response in the PMS was defined as a decrease from baseline in PMS of at least 2 points and at least 25%, with an accompanying decrease in the RBS of at least 1 point or an absolute RBS of 0 or 1. The PMS score is a discrete ordinal scale ranging from 0 (normal or inactive disease) to 9 (severe disease) and is a composite of 3 subscores:

Stool Frequency Subscore, Rectal Bleeding Subscore, and Physician's Global Assessment Subscore, each of which ranges from 0 (normal) to 3 (severe disease).

Two-sided 95% CI for the within-group proportions are based on the Wilson score method.
Week 8
The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
Zeitfenster: From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks
A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
From the first dose of investigational product (IP) and no later than 28 days after the last dose of IP for those who had completed the study or discontinued (D/C) early; maximum duration of exposure to treatment was 12.00 weeks
The Number of Participants Who Discontinued Apremilast Due to Treatment Emergent Adverse Events During the Placebo-Controlled Period
Zeitfenster: From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.
From the first dose of IP and no later than 28 days after the last dose of IP for those who had completed the study or discontinued early; median duration of exposure to treatment was 12.00 weeks
The Number of Participants Who Experienced TEAEs During the Apremilast (APR) Exposure Period (Active Treatment Phase) Through Week 52
Zeitfenster: From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
From first dose of IP and no later than 28 days after last dose of IP for those who completed the active treatment phase or D/C early; median duration of exposure = 41.00, 44.15 and 40.00 weeks respectively for 30 mg, 40 mg and 30 mg/40 mg APR arms
The Number of Participants Who Experienced TEAEs During Week 52 to Week 104 (Extension Phase)
Zeitfenster: From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.
A TEAE was defined as any AE occurring or worsening on or after the first treatment of apremilast and up to 28 days after the last apremilast dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain
From the first dose of IP at Week 52 and no later than 28 days after the last dose of IP for those who completed the study or had discontinued early; median exposure of apremilast for the total apremilast group was 52 weeks.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Amgen

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. Januar 2015

Primärer Abschluss (Tatsächlich)

25. September 2017

Studienabschluss (Tatsächlich)

3. Juni 2019

Studienanmeldedaten

Zuerst eingereicht

10. November 2014

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2014

Zuerst gepostet (Schätzen)

13. November 2014

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

7. Mai 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. April 2020

Zuletzt verifiziert

1. April 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CC-10004-UC-001
  • 2014-002981-64 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

Ja

Beschreibung des IPD-Plans

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

IPD-Sharing-Zeitrahmen

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

IPD-Sharing-Zugriffskriterien

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Art der unterstützenden IPD-Freigabeinformationen

  • Studienprotokoll
  • Statistischer Analyseplan (SAP)
  • Einwilligungserklärung (ICF)
  • Klinischer Studienbericht (CSR)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Colitis ulcerosa

Klinische Studien zur Placebo

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Sweden

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren